Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC

Published:2020-09 Issue:9 Volume:15 Page:1472-1483
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dumoulin Daphne W.,Visser Sabine,Cornelissen Robin,van Gelder Teun,Vansteenkiste Johan,von der Thusen Jan,Aerts Joachim G.J.V.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference56 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Adverse renal effects of immune checkpoint inhibitors: a narrative review;Wanchoo;Am J Nephrol,2017

4. Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

5. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage;Rombolà;J Nephrol,2015

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

2. Cancer therapy in patients with reduced kidney function;Nephrology Dialysis Transplantation;2024-06-24

3. Nefrotoxicidad asociada a la combinación de cisplatino e inhibidores del punto de control inmunitario. Estudio histopatológico;FarmaJournal;2024-06-17

4. Harnessing the innate immune system by revolutionizing macrophage-mediated cancer immunotherapy;Journal of Biosciences;2024-06-04

5. Cancer drugs and acute kidney injury: new therapies and new challenges;Current Opinion in Nephrology & Hypertension;2024-05-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3